Clinical Studies

Gynecologic Oncology Group (GOG) Studies

The Gynecologic Oncology Group (GOG) is an international cooperative group funded by the National Cancer Institute.  The goals of the group are to promote excellence in the quality and integrity of clinical trials in gynecologic malignancies.  The Milton S. Hershey Medical Center is one of 48 "parent" institutions with over 200 affiliate institutions in the United States.  Our affiliates include Lehigh Valley Hospital, The University of Utah, West Virginia University, and The University of Maryland.  Approximately 45 individual trials are active at any on time within the GOG for patients with a variety of gynecologic malignancies, including cancers that arise from the ovaries, uterus, cervix, vagina and vulva.

Eligibility Criteria

  • For information on eligibility criteria for the GOG studies listed below, contact Ann Gelder at 717-531-6218 or email agelder@psu.edu

Study Protocol

  • Site: Ovary
    • GOG 146-P-Phase II Evaluation of Cetuximab Combination with Carboplatin in the Treatment of Recurrent Platinum-Sensitive Ovarian or Primary Peritoneal Cancer
    • GOG 146-Q-Phase II Evaluation of Topotecan Administered Daily Times 5 days every 3 Weeks vs. Weekly Topotecan in the Treatment of Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
    • GOG 175-Randomized Phase III Trial of Carboplatin and Taxol Q 21 days for 3 courses Plus Low dose Paclitaxel vs. Carboplatin and Taxol Q 21 days for 3 courses Plus Observation in Patients with Early Stage Ovarian Cancer
    • GOG 198-Randomized Study of Tamoxifen vs. Thalidomide in Patients with Biochemical Recurrence only Epithelial Ovarian Cancer, Cancer of the Fallopian Tube, and Primary Peritoneal Carcinoma after 1st Line Chemotherapy
    • GOG 212-Randomized Phase III Trial of Maintenance chemotherapy Comparing 12, Monthly Cycles of Single Agent Paclitaxel or Xyotax vs. No Treatment Until Documented Relapse in Women with Advanced Ovarian or Primary Peritoneal Cancer Who Achieve a Complete Clinical Response to Primary Platinum/Taxane Chemotherapy
    • GOG 218-Phase III Trial of Carboplatin and Paclitaxel Plus Placebo vs. Carboplatin and Paclitaxel Plus Concurrent Bevacizumab Followed by Placebo, vs. Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women with Newly Diagnosed, Previously Untreated, Suboptimal advanced Stage Epithelial Ovarian and Primary Peritoneal Cancer
     
  • Site: Endometrial
    • GOG 129-N-Phase II Evaluation of Weekly Docetaxel in the Treatment of Recurrent or Persistent Endometrial Carcinoma
    • GOG 209-Randomized Phase III Trial of Doxorubicin/Cisplatin/Paclitaxel and G-CSF vs. Carboplatin/Paclitaxel in Patients with Stage III and IV or Recurrent Endometrial Cancer
    • GOG 210-A Molecular Staging of Endometrial Carcinoma
    • GOG 211-Phase II Pilot Investigation of the Relationship of Short Term Depo-Provera Exposure to the Morphologic, Biological, and Molecular Changes in Primary endometrial Adenocarcinoma
     
  • Site: Cervix
    • GOG 204-Randomized Phase III Study of Paclitaxel Plus Cisplatin vs. Vinorelbine Plus Cisplatin vs. Gemcitabine Plus Cisplatin vs. Topotecan Plus Cisplatin in Stage IVB, Recurrent, or Persistent Carcinoma of the Cervix.
     
  • Site: Uterine Sarcoma
    • GOG 87-L-Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Advanced Leiomyosarcoma of the Uterus
    • GOG 131-G-Phase II Evaluation of Docetaxel and Gemcitabine Plus G-CSF in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus
     
  • Site: Vulva
    • GOG 173-Intraoperative Lymphatic Mapping and Sentinel Node Identification in Patients with Squamous Cell Carcinoma of the Vulva
    • GOG 205-Phase II Trial of Radiation Therapy and Weekly Cisplatin Chemotherapy for the Treatment of Locally Advanced Squamous Cell carcinoma of the Vulva
     
  • Site: Gestational Trophoblastic Disease
    • GOG 174-Randomized Phase III Trial of Weekly Parenteral Methotrexate vs. Pulsed Dactinomycin as Primary Management of Low Risk Gestational Trophoblastic Neoplasia.